seekingalpha.com
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Skye Bioscience, Inc.SKYENASDAQ
Loading
Latest News
Loading news...
globenewswire.com
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025, along with key accomplishments and upcoming milestones.
globenewswire.com
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Tuesday, March 10th at 1:30 p.m. PT/4:30 p.m.
defenseworld.net
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, four have assigned a buy recommendation
benzinga.com
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year
Skye Bioscience, Inc. (NASDAQ: SKYE) on Monday shared interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab.
globenewswire.com
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab doses Weight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantage Strong safety and tolerability profile maintained — no serious adverse events or adverse events of special interest reported during the 52-week extension period SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond™ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody.
globenewswire.com
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model" at Keystone's conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects. Skye's presentation addressed the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody: Can nimacimab enhance optimal and suboptimal doses of incretin agonists?
globenewswire.com
Skye Bioscience to Present Poster at Keystone Obesity Conference
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a poster at Keystone's conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects. Skye's presentation addresses the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody: Can nimacimab enhance optimal and suboptimal doses of incretin agonists?
globenewswire.com
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breached their fiduciary duties to shareholders.
defenseworld.net
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, four have issued a buy
prnewswire.com
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE
LOS ANGELES, Jan. 19, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
prnewswire.com
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Jan. 19, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before January 16, 2026.
prnewswire.com
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
NEW YORK, Jan. 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline. So what: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
newsfilecorp.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" or the "Company") (NASDAQ: SKYE) and reminds investors of the January 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
newsfilecorp.com
SKYE DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SKYE
New York, New York--(Newsfile Corp. - January 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline.
globenewswire.com
SKYE BIOSCIENCE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options
globenewswire.com
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 16, 2026.
newsfilecorp.com
DEADLINE TOMORROW: Berger Montague Advises Skye Bioscience, Inc. (SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive. Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026, seek to be appointed as a lead plaintiff representative of the class.
prnewswire.com
Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.